Mazdutide
Also known as: IBI362, LY3305677
Dual GLP-1/glucagon receptor agonist (Fc-fusion); long-acting weekly for obesity and T2D with strong weight loss signals.
- Typical dose
- 3 mg – 9 mg
- Frequency
- once weekly
- Route
- Subcutaneous
- Half-life
- 7 days
- Routes
- Subcutaneous
- Status
- Investigational: Phase III (approved in China)
Benefits
- Up to 15% body weight loss
- Weekly dosing
- Blood sugar control
- Appetite suppression
Dosing
A common research range for Mazdutide is 3 mg to 9 mg once weekly. Titrate from 3mg to 9mg weekly. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Mazdutide has an approximate half-life of 7 days. Vial can display informational half-life estimates when supported data is available. These estimates are not measured blood concentrations or dosing instructions.
Storage
2-8°C.
Reported side effects
- Nausea
- Diarrhea
- Decreased appetite
Contraindications
- MEN2
- Pancreatitis
Track Mazdutide with Vial
Vial logs every Mazdutide dose, organizes your schedule, and offers reconstitution math and supported half-life estimates. Tracking records stay on your device. A Vial Pro subscription is required. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Mazdutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.